Showing 711-720 of 2222 results for "".
- Nilvadipine Slowed Cognitive Decline in Early- but not Late-Stage Alzheimer Disease in Clinical Trial Post Hoc Analysishttps://practicalneurology.com/news/nilvadipine-slowed-cognitive-decline-in-early-but-not-late-stage-alzheimer-disease-in-clinical-trial-post-hoc-analysis/2469182/New data from a clinical NILVAD trial (NCT02017340) of nilvadipine (Alzforum, Archer Pharmaceuticals, Sarasota, FL) Alzheimer disease (AD) using nilvadipine identified that individuals with very m
- Vazegepant Relieves Pain And Most Bothersome Symptoms in Phase 2/3 Trialhttps://practicalneurology.com/news/vazegepant-relieves-pain-and-most-bothersome-symptoms-in-phase-23-trial/2469112/In a pivotal phase 2/3 clinical trial (NCT03872453), vazegepant (Biohaven Pharmaceutical, New Haven, CT). Participants in the trial (n=1,673) were randomly assigned to receive 5 mg, 10 mg, or 20 m
- Cenobamate Reduces Seizure Frequency Significantly in Phase 2 Trialhttps://practicalneurology.com/news/cenobamate-reduces-seizure-frequency-significantly-in-phase-3-trial/2469075/In the phase 2 trial (NCT01866111) treatment with cenobamate (SK Life Science, Paramus, NJ) resulted in statistically significant greater reductions in focal seizure frequency compared with baseline. Those treated with cenobamate 100 m
- Vamorolone Has Efficacy for Treating Duchenne Muscular Dystrophy Without Affecting Growthhttps://practicalneurology.com/news/vamorolone-has-efficacy-for-treating-duchenne-muscular-dystrophy-without-affecting-growth/2470013/In the VISION-DMD trial (NCT02760277), children with Duchenne muscular dystrophy (DMD) treated with vamorolone (ReveraGen BioPharma, Rockville, MD), had improved motor function with no negative effects on linear growth or biomarkers of
- Sargramostim Improves Motor Symptoms of Parkinson Disease in Small Phase 1 Trialhttps://practicalneurology.com/news/sargramostim-improves-motor-symptoms-of-parkinson-disease-in-small-phase-1-trial/2469597/An investigator-initiated clinical trial (NCT03790670) evaluated the use of sargramostim (Leukine; Partner Therapeutics, Lexington, MA). Improvements in MDS-UPDRS Part 3 scores, which measure motor sympto
- Validation of an Algorithmic EEG-Based Diagnostic Tool for Concussionhttps://practicalneurology.com/news/validation-of-an-algorithmic-eeg-based-diagnostic-tool-for-concussion/2469505/A study validating an EEG-based algorithmic concussion assessment tool (Concussion Index; Brainscope, Bethesda, MD) has been published in JAMA Open Network for evaluating severity of concussion
- Cannabidiol Reduces Seizures in People With Tuberous Sclerosis Complex-Related Seizures in Clinical Trialshttps://practicalneurology.com/news/cannabidiol-reduces-seizures-in-people-with-tuberous-sclerosis-complex-related-seizures-in-clinical-trials/2469097/Findings from a clinical trial (NCT02544763) presented at the American Epilepsy Society Annual Meeting December 6-10, 2019 in Baltimore, MD showed that people with tuberous sclerosis complex (TSC), a genetic condition associated with t
- Positive Phase 2 Results for Evobrutinib Treatment of MS and Initiation of Phase 3 Trialshttps://practicalneurology.com/news/positive-phase-2-results-for-evobrutinib-treatment-of-ms-and-initiation-of-phase-3-trials/2469014/At the European Committee on Research and Treatment in Multiple Sclerosis (ECTRIMS) Congress in Stockholm, Sweden September 11-13, 2019, data from a phase 2 trial (NCT02975349) of evobrutinib (EMD Serono, Rockland, MD) for treatment of
- Eye Tracking Technology Detects Traumatic Brain Injury With Sensitivity and Specificityhttps://practicalneurology.com/news/eye-tracking-technology-detects-traumatic-brain-injury-with-sensitivity-and-specificity/2469003/Research findings published in Concussion show that measurement of horizontal saccades with eye-tracking technology (Brain Health EyeQ; RightEye, Bethesda, MD) has a 77% sensitivity and 78% specificity for i
- Commercial Launch of Sensing Technology for Closed-Loop Spinal Cord Stimulation System Announcedhttps://practicalneurology.com/news/commercial-launch-of-sensing-technology-for-closed-loop-spinal-cord-stimulation-system-announced/2475782/Saluda Medical (Minneapolis, MN) has announced the full commercial launch of EVA Sensing Technology to support the treatment of people with chronic pain conditions. The device is designed to be used with the company’s closed-loop spinal cord stimulation system—the Evoke SmartLoop System (Saluda M